Todd Fralich

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

Frank J. Palella, Martin Fisher, Pablo Tebas et al. · AIDS · 2013 · 118 citations

Medicine, Pharmacology, Pharmacotherapy +17

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

Calvin Cohen, David A. Wohl, José Ramón Arribas et al. · AIDS · 2014 · 109 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study

Fred Saad, Maha Hussain, Bertrand Tombal et al. · European Urology · 2024 · 52 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients

Samir K. Gupta, Albert M. Anderson, Ramin Ebrahimi et al. · PLoS ONE · 2014 · 51 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Rafael Campo, E DeJesus, U. Fritz Bredeek et al. · Clinical Infectious Diseases · 2013 · 49 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17